Added to YB: 2026-01-20
Pitch date: 2026-01-17
NVO [bullish]
Novo Nordisk A/S
-19.41%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 381.45
Price Target
78.00 (-75%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Novo Nordisk ($NVO): The signal through the noise, JPM week, and Oral launch
NVO: Wegovy oral launch exceptionally strong w/ 3,071 retail scripts in 4 days (excludes DTC channels). $149 pricing undercuts Lilly's vial 60%, democratizing GLP-1 access for 85M untreated Americans. New CEO refocusing on metabolic ecosystem vs single drug. PT $78 in 2026.
Read full article (4 min)